BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following conferences:

  • Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET.
  • 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET.
  • Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m. ET.
  • Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024, at 9:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn.

BCRXW

Contact:

John Bluth





EN
07/05/2024

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

Jonathan Moreland
  • Jonathan Moreland
Free Trial
BCRX BioCryst Pharma...
SABR SABRE CORP. ... (+12)

InsiderInsights.com Daily Ratings Report: May 15, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

BCRX BIOCRYST PHARMACEUTICALS INC.
SABR SABRE CORP.
AAOI APPLIED OPTOELECTRONICS INC.
HAIN THE HAIN CELESTIAL GROUP
AVRO INC.
HQI AVROBIO
FTHM HIREQUEST INC.
HUMA FATHOM HOLDINGS
BHVN HUMACYTE INC
GRNT BIOHAVEN LTD
GNLX GRANITE RIDGE RESOURCES INC
GENELUX CORP
05/16/24 May 16, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present New Data at 2024 Meeting of the European Academy o...

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024.  BioCryst will present two abstracts at the meeting: Adverse Health Outcomes and Patient and Ph...

May 14, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

ORLADEYO® (berotralstat) Approved in Mexico

ORLADEYO® (berotralstat) Approved in Mexico RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “With this decision by COFEPRIS, ORLADEYO is now approved in four countries in the pan-Latin America region. We are proud to work with our partner, Pint Pharma, to bring our oral, once-...

May 13, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Presents New Real-world Evidence Showing Significant Reductio...

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at t...

May 9, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET. 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET. Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET. H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday...

May 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch